HEALTH

Neptune signs John Elway as pitchman for krill oil product

BY Michael Johnsen

LAVAL, Quebec — Neptune Technologies and Bioressources on Tuesday announced that Denver Broncos EVP football operations and retired star quarterback John Elway has signed on as a spokesman for the company’s Neptune Krill Oil brand.

"This is an exceptional day for our company and we could not be more pleased to partner with one of the best professional football players to ever play the game," Neptune president and CEO Henri Harland said.

The move may be in preparation of a U.S. retail launch. In February, Neptune announced that Jamieson Labs would license Neptune’s krill oil product as Jamieson Omega-3 Super Krill across the Canadian health-and-wellness marketplace. “We have been watching krill as an ingredient for several years, and are bringing it to market at the right time and with the right partner," stated Jillan Mariani, director brand marketing for Jamieson.

For a video featuring Elway’s support of the product, click here.


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

HEALTH

Circling germ protection

BY Michael Johnsen

LAS VEGAS — Oasis Consumer Healthcare’s Halo oral antiseptic ought to make a big splash in the 2012-2013 cough-cold season. The new product launched in late February at an ECRM conference in Las Vegas and was voted “Best New Product” by retail buyers attending the event.


The Halo antiseptic spray is designed to coat the back of the throat for up to six hours to help to protect against airborne germs. Suggested retail price for Halo is $12.99, and the product will be merchandised alongside immunity system boosters in the cough-cold aisle.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

HEALTH

Tums touts a ‘fresh’ take

BY Michael Johnsen

Tums has proven to be the Houdini of digestive tablets — surviving all digestive switch products from H2 blockers through proton-pump inhibitors, and still growing. For the 12 weeks ended Jan. 12, sales of Tums were up more than 3%, and it still was among the top three antacids.


GSK’s latest Tums innovation comes in the form of Tums Freshers, a new tablet-size version of Tums that is 40% smaller than regular Tums and includes a cooling flavor for breath freshening because 94% of heartburn sufferers also report having bad breath when they experience heartburn, according to a recent GSK survey.

 

 

The article above is part of the DSN Category Review Series. For the complete Antacids Sell-Through Report, including extensive charts, data and more analysis, click here.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES